# Myostatin (GDF-8) > The body’s brake on muscle growth — a TGF-β-family growth factor whose inhibition is the leading strategy to preserve muscle, including during GLP-1 weight loss. - Also known as: GDF-8, Growth differentiation factor 8, MSTN - Class: Growth Hormone, Metabolic - FDA approved: No - Canonical page: https://americanpeptide.com/catalog/myostatin ## Overview Myostatin (GDF-8) is the molecule that limits how much muscle you build. A member of the TGF-β superfamily, it is a negative regulator of skeletal-muscle mass: secreted by muscle itself, it signals muscle to stop growing. That makes myostatin unusual in this catalog — the therapeutic interest is almost entirely in blocking it, not supplying it — and it has become a forward-looking target precisely because the GLP-1 era exposed a problem myostatin inhibition could solve. Myostatin is best understood by what happens when it is missing. Cattle breeds with loss-of-function mutations — the "double-muscled" Belgian Blue — are dramatically more muscular; so are myostatin-null mice, a strain of "bully whippets," and, in a well-documented 2004 case, a human child with a myostatin mutation born unusually strong. The lesson is consistent across species: myostatin is a brake, and releasing it builds muscle. That is why the drug development around it aims to inhibit the pathway — with antibodies, ligand traps, and receptor blockers — rather than administer the growth factor. The clinical targets were originally the diseases of muscle loss: muscular dystrophies, sarcopenia (age-related muscle wasting), and cachexia. Results have been mixed — blocking myostatin reliably adds muscle mass, but translating that into durable strength and function has proven harder — which is the honest state of the field. The forward-looking turn is metabolic. The GLP-1 and dual/triple-agonist drugs produce large weight loss, but a substantial fraction of that loss is lean muscle, not just fat — a growing concern about the *quality* of weight loss as these drugs scale. Myostatin-pathway inhibition is the leading strategy to preserve or build muscle alongside that fat loss, and combinations of incretin agonists with muscle-sparing agents are an active frontier. This is the real "next chapter" beyond first-generation GLP-1 fat loss: not just losing weight, but keeping the muscle. It is also a doping and hype target — "myostatin blockers" are marketed well ahead of the evidence, and the pathway is banned in sport. As a reference entry, myostatin is the target and the science; specific inhibitor drugs are described as research and investigational, not endorsements. ## Mechanism Synthesized as a precursor and processed to a disulfide-linked dimer that signals through the activin type II receptors (ActRIIB) and the Smad2/3 pathway to suppress muscle-fiber growth. Removing or blocking myostatin releases that brake, increasing muscle mass; follistatin is a natural antagonist of this signal. ## Chemistry | Property | Value | | --- | --- | | Molecular weight | 12400 Da | | UniProt | [O14793](https://www.uniprot.org/uniprotkb/O14793) | ## Research areas Studied in: Muscle growth, Body composition, Sarcopenia, Muscular dystrophy, GLP-1 muscle preservation. Guides on this site: - [Longevity & Aging](https://americanpeptide.com/research-areas/longevity-aging): Peptides studied across the aging axis — senescence, NAD+, and resilience. - [Growth Hormone & Body Composition](https://americanpeptide.com/research-areas/growth-hormone-axis): Secretagogues studied for GH release, IGF-1, and body composition. ## Key research - Negative regulator of muscle — loss of myostatin (cattle, mice, dogs, a human case) produces dramatic muscle overgrowth. - Inhibition as the therapeutic angle — antibodies, ligand traps, and receptor blockers aim to release the brake, not supply the factor. - Muscle-wasting disease — studied in muscular dystrophy, sarcopenia, and cachexia; mass gains are more reliable than functional gains so far. - GLP-1 muscle preservation — a leading strategy to counter the lean-mass loss that accompanies incretin-driven weight loss (the forward-looking use). - ActRIIB/Smad signaling — myostatin acts through activin receptors; follistatin is its natural antagonist. - Not an approved drug — no myostatin-targeting therapy is broadly approved; agents remain investigational. ## Storage, handling & synthesis **Storage.** As a research protein, recombinant myostatin/GDF-8 is handled like other growth factors — stored frozen as lyophilized powder, kept cold and protected from repeated freeze–thaw once reconstituted. **Handling.** A disulfide-linked dimeric protein sensitive to heat, repeated freeze–thaw, and agitation, any of which can disrupt the dimer and reduce activity. **Synthesis.** Myostatin is a processed, disulfide-linked dimer of the TGF-β superfamily — not a solid-phase synthetic peptide. Its mature monomer is ~12.4 kDa and the active form is a ~25 kDa dimer; because it is produced and processed in cells (and is studied as a target rather than supplied as a drug), it has no single small-molecule formula. Most therapeutics in this space are antibodies or engineered receptor traps, which are biologic-grade products in their own right. ## FAQs ### What is myostatin? Myostatin (GDF-8) is a TGF-β-family growth factor that limits skeletal-muscle growth — the body’s brake on muscle mass. Most therapeutic interest is in blocking it to increase muscle, not in administering it. ### Why is myostatin relevant to GLP-1 weight loss? GLP-1 and related drugs cause large weight loss that includes significant muscle, not just fat. Inhibiting the myostatin pathway is the leading approach to preserve muscle during that weight loss — a major forward-looking direction. ### Do myostatin blockers work? Blocking myostatin reliably increases muscle mass in studies, but translating that into lasting strength and function has been inconsistent. No myostatin-targeting drug is broadly approved; they remain investigational. ### Is this medical advice? No — this is a research and educational reference. Myostatin-targeting agents are investigational and, as a pathway, are banned in sport. ## Latest research Recent trials and publications mentioning Myostatin, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily). ### Recent trials - [A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation](https://clinicaltrials.gov/study/NCT06299098) — ACTIVE_NOT_RECRUITING · PHASE2 · NCT06299098 - [The Effect of Teleconsultation, on the Reversibility of Frailty in Geriatric Patients Post Hospitalization](https://clinicaltrials.gov/study/NCT07712276) — NOT_YET_RECRUITING · NA · NCT07712276 - [A Two-Way Path to Health: Environmental Influences on Skeletal Muscle Endocrine Function](https://clinicaltrials.gov/study/NCT07706465) — NOT_YET_RECRUITING · NA · NCT07706465 - [A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer](https://clinicaltrials.gov/study/NCT07698314) — NOT_YET_RECRUITING · NA · NCT07698314 - [CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy](https://clinicaltrials.gov/study/NCT07443826) — RECRUITING · PHASE1, PHASE2 · NCT07443826 - [Metabolic Effects of Diet-Exercise Interventions in Obesity](https://clinicaltrials.gov/study/NCT07695480) — COMPLETED · NA · NCT07695480 --- Source: AmericanPeptide.com — https://americanpeptide.com/catalog/myostatin Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com. Research reference only — computational and educational content, not medical advice.